WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

When these cells are confronted with potent new drugs called CDK2 inhibitors, which are designed to prevent cancer from proliferating, they can trigger a workaround to survive the assault in as little ...

"These striking new findings validate the combination of INX-315 with CDK4/6 inhibitors as a promising therapeutic strategy with potential application beyond patients with CDK2-addicted cancers ...

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies. The biopharma has ...

September 14, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with ...

There are currently no approved CDK2 specific drugs. ETX-197/BG-68501 was designed through ENSEM’s Kinetic Ensemble platform to induce previously unexplored interactions within the CDK2 ATP ...

“CDK2 hyperactivity plays a well-recognized role in many cancers but has been an extremely challenging target for drug discovery,” said Shengfang Jin, CEO and Co-Founder of ENSEM. “Through ...

CDK2 molecular glue degrader MRT-51443 shows enhanced tumor regression and delayed resistance in breast cancer models, surpassing standard treatments. Details regarding the clinical development ...

You have full access to this article via your institution. Attention then turned to Cdk2-E in large part due to the temporal correlation between the rise in its activity and the first ...

CDK2-directed MGD drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer when combined with either a CDK4/6 inhibitor or a CDK4 ...

ETX-197/BG-68501 has a differentiated preclinical profile and the potential to deliver clinical benefit to patients with tumors associated with CDK2 dependency. CDK2 is a well-established ...